Evidence-based omeprazole dosing and treatment duration protocols optimize therapeutic benefit while minimizing rebound acid secretion and resistance development in equine gastric disease.
Omeprazole welfare use in horses suffers from significant under-dosing and premature discontinuation in clinical practice. Horses treated for insufficient durations or at maintenance doses during active disease fail to achieve mucosal healing, continuing to experience gastric pain despite apparent treatment. The welfare implication is significant — owners believe their horse is being treated effectively while chronic pain continues. Licensed GastroGard at therapeutic dose for full 28-day courses, confirmed effective by re-endoscopy, is the welfare-appropriate protocol. Management changes concurrent with medication are essential — medication alone without management change produces rapid relapse.